Results for
"[search-keyword]"
Sponsor content
152 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Jardiance (empagliflozin) has been approved for reducing the risk of kidney disease progression in adults with chronic kidney disease.
-
Australian Public Assessment Report (AusPAR)Spevigo (spesolimab) has been approved for the treatment of generalised pustular psoriasis, a rare but severe form of psoriasis that involves flares of widespread, non-infectious, macroscopically visible pustules.
-
Apr-2024Prescription medicine evaluationActive ingredient: Tenecteplase.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPEVIGO spesolimab (rch) 450 mg in 7.5 mL concentrated solution for infusion vial.
-
Prescription medicine registrationActive ingredients: empagliflozin.
-
Prescription medicine decision summarySpevigo (spesolimab) is approved for the treatment of flares in adult patients with generalised pustular psoriasis.
-
Prescription medicine registrationActive ingredients: spesolimab.
-
Aug-2023Prescription medicine evaluationActive ingredient: empagliflozin, metformin hydrochloride.
-
Jul-2023Prescription medicine evaluationActive ingredient: empagliflozin.
-
Cancellation by sponsorRequested by Boehringer Ingelheim Pty Ltd
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »